Mark Diamond

Dr. Mark Diamond is a Clinical Assistant Professor of Medicine in the Division of Hematology-Oncology at the Perelman School of Medicine, University of Pennsylvania. He practices as a Medical Oncologist within Penn Medicine, providing care at the Abramson Cancer Center (Pennsylvania Hospital location) for adult patients (18+). Despite being on Pennsylvania Hospital's medical staff, he lacks inpatient treatment privileges but maintains active outpatient clinical responsibilities and is accepting new patients.

His educational background includes:

• MD/PhD: Washington University in St. Louis
• Residency: NewYork-Presbyterian/Weill Cornell Medical Center
• Fellowship: Hospital of the University of Pennsylvania

Dr. Diamond's research centers on cancer immunology, specifically dendritic cell-mediated tumor immunity and immune escape mechanisms. His work reveals how impaired dendritic cell cross-priming enables site-dependent immune evasion, and investigates therapeutic strategies combining CD40 agonists with checkpoint blockade. Recent studies examine immunoediting in pancreatic cancer and sarcoma treatment outcomes using National Cancer Database analytics. This research spans fundamental immunology (e.g., Batf3-dependent dendritic cell functions) to clinical applications in melanoma and solid tumor immunotherapy.

His publication record demonstrates consistent output in high-impact journals (Science, Nature Immunology, PNAS) from 2005-2021, reflecting sustained research activity. Clinically, he maintains exceptional patient satisfaction ratings (5.0/5.0 from 312 reviews) with specific praise for communication and responsiveness. Dr. Diamond operates within Penn Medicine's extensive research ecosystem, collaborating with the Abramson Cancer Center's immunotherapy teams while contributing to both laboratory-based immunology and clinical oncology advancements.